KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Other Non-Current Liabilities (2016 - 2025)

Historic Other Non-Current Liabilities for Vertex Pharmaceuticals (VRTX) over the last 17 years, with Q3 2025 value amounting to $1.2 billion.

  • Vertex Pharmaceuticals' Other Non-Current Liabilities rose 3215.47% to $1.2 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.2 billion, marking a year-over-year increase of 3215.47%. This contributed to the annual value of $1.0 billion for FY2024, which is 1559.76% up from last year.
  • Per Vertex Pharmaceuticals' latest filing, its Other Non-Current Liabilities stood at $1.2 billion for Q3 2025, which was up 3215.47% from $1.2 billion recorded in Q2 2025.
  • In the past 5 years, Vertex Pharmaceuticals' Other Non-Current Liabilities registered a high of $1.2 billion during Q3 2025, and its lowest value of $127.2 million during Q3 2022.
  • Its 5-year average for Other Non-Current Liabilities is $646.2 million, with a median of $759.3 million in 2023.
  • Per our database at Business Quant, Vertex Pharmaceuticals' Other Non-Current Liabilities plummeted by 5601.14% in 2021 and then soared by 58341.19% in 2023.
  • Over the past 5 years, Vertex Pharmaceuticals' Other Non-Current Liabilities (Quarter) stood at $303.3 million in 2021, then skyrocketed by 126.11% to $685.8 million in 2022, then increased by 27.98% to $877.7 million in 2023, then grew by 15.6% to $1.0 billion in 2024, then grew by 21.57% to $1.2 billion in 2025.
  • Its Other Non-Current Liabilities stands at $1.2 billion for Q3 2025, versus $1.2 billion for Q2 2025 and $951.9 million for Q1 2025.